글로벌 뇌종양 진단 및 치료 시장 규모, 점유율 및 추세 분석 보고서 – 산업 개요 및 2031년까지의 예측

뇌종양 진단 및 치료 시장 분석

뇌종양 진단 및 치료 시장은 생명공학 및 분자 연구의 발전에 힘입어 상당한 성장을 경험하고 있습니다. 이 분야의 발전에는 더 높은 효율성과 세포 구성 요소의 더 나은 보존을 제공하는 혁신적인 세포 용해 기술의 도입이 포함됩니다. 이제 기업들은 다양한 연구 워크플로에 원활하게 통합되는 보다 정교하고 자동화된 시스템을 개발하는 데 주력하고 있습니다. 예를 들어, 마이크로유체 장치와 음향 용해 시스템의 도입은 연구자들이 세포 샘플을 처리하고 처리하는 방식에 혁명을 일으켜 용해 과정을 정확하게 제어하고 샘플 손실을 최소화했습니다. 또한 시약 제형의 발전과 새로운 소모품의 개발은 뇌종양 진단 및 치료 기술의 다양성과 효과를 향상시키고 있습니다. 이 시장은 또한 제약 및 생명공학 기업의 연구 개발에 대한 투자 증가와 개인화된 의학 및 재생 치료에 대한 강조가 커짐에 따라 혜택을 받고 있습니다.

뇌종양 진단 및 치료 시장 규모

글로벌 뇌종양 진단 및 치료 시장 규모는 2023년에 6억 1,828만 달러로 평가되었으며, 2031년까지 1,12923만 달러에 도달할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 CAGR은 7.82%입니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

뇌종양 진단 및 치료 시장 동향

“ 효소 세포 분리 방법의 채택 증가”

The brain tumor diagnosis and treatment market is growing due to advancements in imaging technologies and personalized medicine. A key trend in the market is the increasing adoption of liquid biopsy techniques for early and non-invasive diagnosis. Liquid biopsies, which analyze circulating tumor DNA (ctDNA) in the bloodstream, offer a less invasive alternative to traditional tissue biopsies. For instance, companies such as Biocept have developed liquid biopsy platforms that detect brain tumor biomarkers, allowing for earlier diagnosis and improved treatment planning. Such technology is especially beneficial for monitoring tumor progression and treatment response in real-time. Additionally, advancements in targeted therapies, such as immunotherapy and precision radiation, are providing more effective treatment options with fewer side effects. These innovations, combined with the rising incidence of brain tumors and the demand for minimally invasive diagnostic tools, are driving the growth of the brain tumor diagnosis and treatment market, improving patient outcomes and enhancing market potential.

Report Scope and Brain Tumor Diagnosis and Treatment Market Segmentation

Brain Tumor Diagnosis and Treatment Market Definition

Brain tumor diagnosis and treatment refer to the medical processes used to identify and manage abnormal growths of cells in the brain. Diagnosis typically involves imaging technologies like MRI (Magnetic Resonance Imaging) and CT (Computed Tomography) scans to detect tumors, alongside techniques such as biopsy, where a sample of the tumor is examined. Emerging methods like liquid biopsies and molecular diagnostics are also being used for non-invasive detection. Treatment encompasses various approaches depending on the tumor's type, location, and stage, including surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy. The goal is to remove or shrink the tumor while minimizing damage to healthy brain tissue and preserving neurological function.

Brain Tumor Diagnosis and Treatment Market Dynamics

Drivers

• Rising Incidence of Brain Tumors

The rising incidence of brain tumors significantly drives the brain tumor diagnosis and treatment market. According to the Global Cancer Burden and Strategies for Cancer Control (GLOBOCAN) 2020 report, there were 19.3 million new cancer cases globally in 2020, with nearly 10.0 million deaths attributed to cancer. The increasing prevalence is influenced by factors such as environmental exposures to radiation and chemical pollutants, along with genetic predispositions. As brain tumor cases continue to rise, the demand for advanced diagnostic tools, such as high-resolution imaging and molecular diagnostics, is escalating, alongside a growing need for innovative treatment options including targeted therapies and immunotherapies. The surge in incidence directly fuels the need for continued development and adoption of cutting-edge solutions, driving growth in the brain tumor diagnosis and treatment market.

• Growing Awareness and Screening Programs

Growing awareness and screening programs are significantly impacting the early detection and diagnosis of brain tumors, leading to increased demand for diagnostic and therapeutic solutions. Public health initiatives and educational campaigns are playing a crucial role in this shift. For instance, organizations such as the American Brain Tumor Association (ABTA) run awareness campaigns that educate public about brain tumor symptoms and the importance of early screening. Such efforts have been linked to increased participation in screening programs, such as MRI scans for individuals at higher risk or those experiencing symptoms. "Brain Tumor Awareness Month" campaign, which raises awareness about the signs of brain tumors and encourages timely medical consultation is further disseminating the awareness and screening programs. As more people become aware of the importance of early detection and seek out screening services, the demand for advanced diagnostic tools and effective treatment options rises, further propelling growth in the brain tumor diagnosis and treatment market.

Opportunities

• Advancements in Imaging Technologies

Advancements in imaging technologies are significantly enhancing the accuracy and effectiveness of brain tumor diagnosis. For instance, the development of advanced MRI techniques, such as high-field MRI and functional MRI (fMRI), offers detailed insights into brain activity and tumor morphology, improving tumor localization and characterization. Additionally, molecular imaging technologies, including positron emission tomography (PET) with radiolabeled tracers, provide valuable information on metabolic activity and tumor cell proliferation, which is crucial for assessing tumor behavior and response to treatment. Specifically, 18F-FDG PET scans have demonstrated the ability to accurately differentiate between tumor types and evaluate treatment efficacy in brain tumor patients. Such innovations not only enhance diagnostic precision but also create opportunities for companies to develop and market cutting-edge imaging solutions, meeting the growing demand for advanced diagnostic tools in the brain tumor market.

• Expansion of Targeted Therapies and Immunotherapies

The expansion of targeted therapies and immunotherapies is transforming the treatment landscape for brain tumors, providing new avenues for combating these challenging conditions. Targeted therapies focus on specific genetic mutations that drive tumor growth, offering a more tailored approach to treatment. For instance, temozolomide is a chemotherapy drug designed to target the DNA repair mechanisms unique to certain brain tumors, such as glioblastomas. Immunotherapies, such as CAR-T cell therapy, where T cells are engineered to recognize and attack tumor cells, showing potential in treating brain tumors such as glioblastoma by targeting cancer cells while minimizing damage to healthy tissue. Companies that invest in these advanced treatment options can capitalize on these innovations, meeting the rising demand for effective brain tumor therapies and improving patient outcomes. Consequently creating great opportunities in the market growth.

Restraints/Challenges

• Complexity of Brain Tumors

The complexity of brain tumors presents a significant challenge in both diagnosis and treatment, as these tumors exhibit considerable variability in their types, locations, and genetic profiles. For instance, glioblastomas, a highly aggressive type of brain tumor, differ markedly from meningiomas, which generally have a better prognosis and less aggressive behavior. Glioblastomas often have diverse genetic mutations and varying responses to treatment, necessitating highly specialized diagnostic tools such as advanced MRI imaging and genetic profiling to accurately identify and understand the tumor's characteristics. Similarly, treatment plans must be tailored to each tumor's specific genetic and molecular features, requiring a multidisciplinary approach involving neurosurgeons, oncologists, and radiologists. This complexity not only complicates the development of standardized treatment protocols but also makes it challenging to implement personalized therapies consistently. Consequently hampering the brain tumor diagnosis and treatment market.

• Limited Availability of Advanced Diagnostic and Treatment Technologies

The limited availability of advanced diagnostic and treatment technologies significantly impacts the quality of care in the brain tumor market, creating disparities between well-equipped centers and those with fewer resources. For instance, cutting-edge imaging systems such as high-field MRI scanners and PET-CT systems, which are crucial for accurate tumor localization and monitoring, are often found only in specialized centers or high-income countries. Patients in lower-income regions or less developed healthcare settings may not have access to these technologies, leading to delays in accurate diagnosis and suboptimal treatment planning. Such disparity is exemplified by the availability of novel therapeutic agents, such as targeted therapies or immunotherapies, which may only be accessible through clinical trials or in countries with advanced healthcare infrastructure.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Brain Tumor Diagnosis And Treatment Market Scope

The market is segmented on the basis of product type, product analysis, diagnosis type, treatment type, and end-user. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

• Primary Brain Tumor
  • Meningioma
  • Gliomas
  • Astrocytomas
  • Pituitary Tumors
  • Others
• Secondary Brain Tumor

Product Analysis

• Stains and Varnishes
• Shellacs
• Lacquers
• Others

Diagnosis Type

• CT Scan
• MRI
• PET-CT Scan
• Molecular Testing
• EEG
• Others

Treatment Type

• Surgery
• Radiation Therapy
• Targeted Therapy
• Chemotherapy
• Immunotherapy

End User

• Hospitals
• Ambulatory Surgical Centers

Brain Tumor Diagnosis And Treatment Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, product type, product analysis, diagnosis type, treatment type, and end-user as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America leads the brain tumor diagnosis and treatment market, primarily due to significant research and development efforts, a high incidence of brain tumor diagnoses, and increasing awareness of treatment and management options. The region's advanced healthcare infrastructure, coupled with substantial investments in oncology research, further strengthens its dominance in this market. Additionally, growing public awareness about early diagnosis and available treatment methods contributes to the rising demand for advanced brain tumor therapies in North America.

Europe is projected to witness the highest growth rate in the brain tumor diagnosis and treatment market during the forecast period of 2024 to 2031. This growth is largely driven by government initiatives aimed at raising awareness of advanced medical technologies and improving access to cutting-edge treatments across the region. Additionally, increased investment in healthcare infrastructure and research, along with growing public awareness about early diagnosis and advanced therapies, is expected to fuel the market's expansion in Europe.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Brain Tumor Diagnosis and Treatment Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Brain Tumor Diagnosis and Treatment Market Leaders Operating in the Market Are:

• 파이저 주식회사(미국)
• 메이요 의학 교육 및 연구 재단(MFMER)(미국)
• GE 헬스케어(미국)
• 아스트라제네카(영국)
• 머크앤코(미국)
• 지멘스 헬스키니어스 AG(독일)
• 케어스트림 헬스(미국)
• 히타치 주식회사(일본)
• Koninklijke Philips NV(네덜란드)
• 시마즈 주식회사(일본)
• 캐논 메디컬 시스템(일본)
• 에자이 주식회사(일본)
• 엘렉타(스웨덴)
• Varian Medical Systems, Inc. (미국)
• 후지필름 주식회사(일본)
• 난토믹스(미국)
• 홀로직 주식회사(미국)
• Thermo Fisher Scientific Inc. (미국)
• 제넨텍 주식회사(미국)
• 브리스톨-마이어스 스퀴브 회사(미국)

뇌종양 진단 및 치료 시장의 최신 동향

• 2024년 3월, AstraZeneca는 Fusion Pharmaceuticals 인수를 완료하여 암 치료의 발전을 가속화하고자 합니다. 이 인수는 화학 요법 및 방사선 요법과 같은 기존 치료법에서 벗어나 환자 결과를 향상시키는 보다 혁신적이고 타겟팅된 접근 방식으로 전환하는 데 중점을 두고 있습니다.
• 2024년 1월, GE HealthCare는 AI 기반 이미징 및 워크플로 솔루션을 전문으로 하는 회사인 MIM Software를 인수했습니다. 이 인수를 통해 GE HealthCare는 MIM의 고급 AI 지원 도구를 종양학 및 신경학과 같은 분야에 통합하여 이러한 중요한 의료 분야에서 진단 정확도를 높이고 치료 계획을 개선할 수 있습니다.

SKU-60266